LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Kodu・Aktsiate loetelu・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Suletud

SektorTervishoid

14.14 -1.46

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13.96

Max

14.44

Põhinäitajad
By Trading Economics
Sissetulek	-445K -19M
Müük	-3.2M 15M
Aktsiakasum	-0.87
Kasumimarginaal	-123.636
Töötajad	120
EBITDA	-883K -16M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+8.56% upside

Turustatistika
By TradingEconomics
Turukapital	39M 409M
Eelmine avamishind	15.6
Eelmine sulgemishind	14.14

Uudiste sentiment

By Acuity

29%

71%

93 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

5.04 / 5.44 Toetus ja vastupanu

ENANTA PHARMACEUTICALS INC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. dets 2025, 22:02 UTC

Tulu

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10. dets 2025, 21:46 UTC

Tulu

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10. dets 2025, 23:52 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10. dets 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

10. dets 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10. dets 2025, 23:20 UTC

Tulu

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10. dets 2025, 23:15 UTC

Tulu

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10. dets 2025, 22:59 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10. dets 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10. dets 2025, 22:40 UTC

Tulu

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. dets 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. dets 2025, 22:06 UTC

Tulu

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. dets 2025, 22:02 UTC

Tulu

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. dets 2025, 22:00 UTC

Tulu

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10. dets 2025, 21:53 UTC

Tulu

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. dets 2025, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10. dets 2025, 21:50 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

10. dets 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10. dets 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. dets 2025, 21:33 UTC

Tulu

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10. dets 2025, 21:32 UTC

Tulu

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10. dets 2025, 21:25 UTC

Tulu

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. dets 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10. dets 2025, 21:16 UTC

Tulu

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10. dets 2025, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10. dets 2025, 21:15 UTC

Tulu

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10. dets 2025, 21:14 UTC

Tulu

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10. dets 2025, 21:14 UTC

Tulu

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Võrdlus sarnastega

Hinnamuutus

ENANTA PHARMACEUTICALS INC Prognoos

Hinnasiht

By TipRanks

8.56% tõus

12 kuu keskmine prognoos

Keskmine 15.6 USD 8.56%

Kõrge 20 USD

Madal 9 USD

Põhineb 5 Wall Streeti analüütiku instrumendi ENANTA PHARMACEUTICALS INC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi ENANTA PHARMACEUTICALS INC aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

5.04 / 5.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

93 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.